I would like to highlight that, for the first time, there was a problem with the funding mechanisms to support high-risk, high-potential projects related to the development of vaccines or therapeutics and to support the science and the companies working on those projects for the COVID-19 therapeutics or vaccines. There was a funding mechanism, an instrument, that was needed to de-risk the investment of the private sector or support the research at a university or academia.
At the same time, it was important for the regulator to have an agile mechanism and to very tightly work with other international regulators in the U.S. or Europe to make sure that the standards were maintained, the quality and safety were in place and protected, and that whatever came out in terms of authorization would be safe and effective.
There were some instruments from the regulatory side that Canada led internationally by allowing clinical trial data to be available to the regulator as it became available, as opposed to waiting for the whole phase to end. It was the speediness in regulatory approval and funding.